Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | LY2275796 |
Synonyms | |
Therapy Description |
LY2275796 is an antisense oligonucleotide targeted against eukaryotic initiation factor 4E (eIF-4E), which results in decreased eIF-4E expression and potentially leads to reduced growth of eIF-4E-expressing tumors (PMID: 17786246, PMID: 21831956, PMID: 27194579). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY2275796 | ISIS 183750|LY-2275796|LY 2275796 | Antisense Therapy 13 | LY2275796 is an antisense oligonucleotide targeted against eukaryotic initiation factor 4E (eIF-4E), which results in decreased eIF-4E expression and potentially leads to reduced growth of eIF-4E-expressing tumors (PMID: 17786246, PMID: 21831956, PMID: 27194579). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|